*2.3. PDMSCs Conditioned Media Ameliorated Maternal Hypertension and Proteinuria in LPS-Induced PE Mouse Model*

We first investigated whether LPS injection was able to induce maternal hypertension. Average maternal basal SBP at days 9–11 was 93.3 ± 1.3 mmHg and it significantly increased to 101.3 ± 1.4 mmHg at day 12 (*p* = 0.04), 24 h after LPS injection (Figure 1B). We next examined the effect of plain media or PDMSCs-CM injection in LPS-induced hypertensive pregnant mice. In control mice (LPS + plain media), maternal SBP continued to increase at day 13 (104.4 ± 1.9) and day 18 (113 ± 2.3), while in CM pregnant females (LPS + PDMSCs-CM), SBP significantly decreased at days 13 (95.6 ± 0.63 mmHg, *p* < 0.01), 15 (95.7 ± 1.2 mmHg, *p* < 0.01), 16 (95.7 ± 2.1 mmHg, *p* = 0.03), and 18 (101.2 ± 2.3 mmHg, *p* < 0.01) relative to control mice (Figure 1B).

On day 12, after LPS injection and before CM or plain media injection, mean mice urine protein concentration was 0.19 ± 0.04 µg/µL. In LPS pregnant females treated by plain media, proteinuria showed a trend of decrease from day 13 to 17 relative to day 12, even though it was not significant and less dramatic compared to CM-treated mice (Figure 1C). Proteinuria decreased on d13 (0.12 ± 0.04, *p* > 0.05), d15 (0.04 ± 0.02, *p* = 0.016), and d17 (0.06 ± 0.02, *p* = 0.045) relative to day 12 CM mice (Figure 1C).

Finally, in order to investigate the effects of plain media or PDMSCs-CM infusion on liver and renal functions in LPS-induced hypertensive pregnant mice, we tested serum levels of selected parameters. On day 19, no differences were found in CM group relative to control in AST (aspartate aminotransferase) (39.75 ± 7.31 mg/dL versus 39.75 ± 5.17, *p* > 0.05) and ALT (alanine transaminase) (247.75 ± 62.88 mg/dL versus 263.75 ± 34.47 mg/dL, *p* > 0.05) levels, used as markers of liver functionality, nor in creatinine (0.0175 ± 0.01 mg/dL versus 0.07 ± 0.01 mg/dL, *p* > 0.05) and urea levels (35.25 ± 5.72 versus 34.25 ± 2.28 mg/dL, *p* > 0.05), used as markers of kidney function.

**Figure 1.** Effects of PDMSCs-CM treatment on maternal parameters during days 11 to 18 of gestation. (**A**) Study design. Blood pressure (**B**) and proteinuria (**C**) in LPS-induced PE mouse model injected with PDMSCs-CM or plain media.
